|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03320 CHINARES PHARMA
Nominal 
5.560 +0.060 (+1.091%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 HKD(K$) | 2021/06 HKD(K$) | 2020/06 HKD(K$) | |
| Turnover | 128,597,588 | 4.705% | 122,818,429 | 125,716,477 | 114,487,606 | 89,387,142 |
| Cost of Sales | (107,664,092) | 4.470% | (103,057,803) | (105,884,796) | (97,022,535) | (74,520,320) |
| Gross Profit | 20,933,496 | 5.935% | 19,760,626 | 19,831,681 | 17,465,071 | 14,866,822 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 HKD(K$) | 2021/06 HKD(K$) | 2020/06 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 198,770 | -6.246% | 212,013 | 185,914 | 142,726 | 75,370 | |
| Profit / (Loss) before Taxation | 7,046,076 | 12.141% | 6,283,235 | 6,581,117 | 5,166,018 | 4,489,640 | |
| Taxation | (1,505,520) | 20.049% | (1,254,086) | (1,412,765) | (1,071,519) | (841,828) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (2,935,750) | 25.060% | (2,347,480) | (2,143,306) | (1,656,393) | (1,070,618) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,604,806 | -2.866% | 2,681,669 | 3,025,046 | 2,438,106 | 2,577,194 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 HKD(K$) | 2021/06 HKD(K$) | 2020/06 HKD(K$) | |
| Net Finance Costs / (Income) | 805,838 | -32.640% | 1,196,310 | 932,461 | 1,201,835 | 1,221,108 |
| Depreciation & Amortisation | 1,628,020 | 6.440% | 1,529,515 | 1,602,815 | 1,365,021 | 1,203,421 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| EPS (cts) | 41.000 | -4.651% | 43.000 | 48.000 | 39.000 | 41.000 |
| DPS (cts) | 8.300 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | 20.244% | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 7.699 | -- | 7.398 | 8.045 | 7.746 | 6.652 |
| Remarks: | Real time quote last updated: 24/12/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,604,806 |
| %Change | -2.866% |
| EPS / (LPS) | RMB 0.410 |
| NBV Per Share (¥) | RMB 7.699 |